Novo Nordisk (NYSE: NVO) plans to expand the number of U.S. employees this year by 15 percent.

Some of those jobs will be added at the Denmark-based company’s insulin manufacturing plant in Clayton, N.C.

Novo Nordisk’s website currently lists 685 job openings across its international operations, including one manufacturing position in Clayton.

Novo Nordisk employs more than 30,000 people worldwide.

“Novo Nordisk has experienced solid growth over the past five years, with an approximately 10 percent increase in U.S. staff per year across a number of specialties,” the company said in a statement from uts U.S. headquarters in Princeton, N.J.. “Recruiting is expected to start immediately.

“The company will be recruiting for new positions across the U.S., with the first hires being made in the coming weeks,” it added. “Beyond the sales team, Novo Nordisk is recruiting for medical liaisons, diabetes educators, and field management positions such as regional directors and business managers.

“In addition to positions supporting its US sales and medical operations, Novo Nordisk continues to recruit for scientific positions in its new type 1 diabetes research center in Seattle, Wash. and for its manufacturing facility in Clayton, N.C.,” Novo Nordisk added.

Said Jerzy Gruhn, president of Novo Nordisk in the U.S.: ”This announcement signals the strength of our business model, the increasing demand for our world-class diabetes products, and the steady output of our robust pipeline. Expanding will provide us the opportunity to better support current business as well as the right structure to meet the future needs of our customers.”